Amgen Inc Stock Buy Recommendation Reiterated (AMGN)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK (TheStreet) -- Amgen (Nasdaq:AMGN) has been reiterated by TheStreet Ratings as a buy with a ratings score of A+ . The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, notable return on equity, reasonable valuation levels and compelling growth in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

• EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

Highlights from the ratings report include:

• AMGN's revenue growth has slightly outpaced the industry average of 5.4%. Since the same quarter one year prior, revenues slightly increased by 9.5%. Growth in the company's revenue appears to have helped boost the earnings per share.
• Powered by its strong earnings growth of 182.00% and other important driving factors, this stock has surged by 57.63% over the past year, outperforming the rise in the S&P 500 Index during the same period. Regarding the stock's future course, although almost any stock can fall in a broad market decline, AMGN should continue to move higher despite the fact that it has already enjoyed a very nice gain in the past year.
• Current return on equity exceeded its ROE from the same quarter one year prior. This is a clear sign of strength within the company. In comparison to the other companies in the Biotechnology industry and the overall market, AMGEN INC's return on equity significantly exceeds that of the industry average and is above that of the S&P 500.
• The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Biotechnology industry. The net income increased by 143.8% when compared to the same quarter one year prior, rising from $454.00 million to $1,107.00 million.

Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada. Amgen has a market cap of $66.74 billion and is part of the health care sector and drugs industry. The company has a P/E ratio of 15.6, below the S&P 500 P/E ratio of 17.7. Shares are up 35.6% year to date as of the close of trading on Wednesday.

You can view the full Amgen Ratings Report or get investment ideas from our investment research center.

--Written by a member of TheStreet Ratings Staff.

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade

For more information on Amgen Inc click any of the following:

• Amgen Inc Stock Price

• Amgen Inc Analyst Ratings

• Amgen Inc Key Stats & Profile

• Amgen Inc Earnings

• Amgen Inc Ratio Comparison

• Amgen Inc Growth Rates

• Amgen Inc Balance Sheet

• Amgen Inc Cash Flow

• Amgen Inc Income Statement